Dopamine/Serotonin Receptor Ligands. 13: Homologization of a Benzindoloazecine-Type Dopamine Receptor Antagonist Modulates the Affinities for Dopamine D1−D5 Receptors
Authors:
- 16 September 2006
- journal article
- research article
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 49 (21) , 6408-6411
Abstract
Enlarging the 10-membered ring of 7-methyl-6,7,8,9,14,15-hexahydro-5H-indolo[3,2-f][3]benzazecine (1, LE 300) yielded two homologue antagonists. Their affinities and inhibitory activities at D1−D5 receptors were measured by radioligand binding experiments and a functional Ca2+ assay. Compared to 1, phenylpropyl homologue 3 was superior in selectivity and affinity for the D5 subtype (Ki = 0.6 nM), whereas the affinity of the indolylpropyl homologue 2 for all subtypes decreased. Compounds 2, 3, 10, 11, 17, and 18 are derivatives of novel heterocyclic ring systems.Keywords
This publication has 7 references indexed in Scilit:
- Dopamine/Serotonin Receptor Ligands. 12: SAR Studies on Hexahydro-dibenz[d,g]azecines Lead to 4-Chloro-7-methyl-5,6,7,8,9,14-hexahydrodibenz[d,g]azecin-3-ol, the First Picomolar D5-Selective Dopamine-Receptor AntagonistJournal of Medicinal Chemistry, 2006
- Dopamine/Serotonin Receptor Ligands. 10: SAR Studies on Azecine-type Dopamine Receptor Ligands by Functional Screening at Human Cloned D1, D2L, and D5 Receptors with a Microplate Reader Based Calcium Assay Lead to a Novel Potent D1/D5 Selective AntagonistJournal of Medicinal Chemistry, 2005
- Dopamine/serotonin receptor ligands. Part VIII[1]:the dopamine receptor antagonist LE300 - modelled and X-ray structure plus further pharmacological characterization, including serotonin receptor binding, biogenic amine transporter testing and in vivo testingsEuropean Journal of Medicinal Chemistry, 2004
- Dopamine Receptor Ligands. Part VII [1]: Novel 3-Substituted 5-Phenyl-1, 2, 3, 4, 5, 6-hexahydro-azepino-[4, 5-b]indoles as Ligands for the Dopamine ReceptorsArchiv der Pharmazie, 2003
- Pharmacological characterization of the benz[ d ]indolo[2,3- g ]azecine LE300, a novel type of a nanomolar dopamine receptor antagonistNaunyn-Schmiedeberg's Archives of Pharmacology, 2002
- 7-Methyl-6,7,8,9,14,15-hexahydro-5H-benz[d]indolo[2,3-g]azecine: A New Heterocyclic System and a New Lead Compound for Dopamine Receptor AntagonistsJournal of Medicinal Chemistry, 2000
- Oxidation of Benzyl Ethers via Phase Transfer CatalysisSynthetic Communications, 1999